Advanced Biliary Tract Cancer Clinical Trial
Official title:
NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer
This is a study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy.
This is a single arm, open label, multicenter phase II study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy. Patients with advanced biliary tract cancers who have adequate performance status and adequate hepatic and renal function will be eligible. Patients may have received adjuvant chemotherapy and/or radiation therapy prior to enrolling in the trial, but a minimum of 6 months between adjuvant chemotherapy and this current therapy are required. Patients may continue on study as long as they are tolerating treatment and do not have progression of disease by RECIST v1.1 criteria. Response assessments will occur using imaging (CT or MRI) every 8 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05009953 -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05820906 -
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT03358849 -
Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer
|
Phase 1 | |
| Recruiting |
NCT05410197 -
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
|
Phase 2 | |
| Active, not recruiting |
NCT04727996 -
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05823987 -
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
|
Phase 2 | |
| Not yet recruiting |
NCT04733521 -
A Phase 1/2 Study of SC-43 in Combination With Cisplatin
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04027764 -
Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05781074 -
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）
|
Phase 2 | |
| Recruiting |
NCT04781192 -
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05653180 -
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04217954 -
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
|
Phase 2 | |
| Recruiting |
NCT05170438 -
Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
|
Phase 2 | |
| Active, not recruiting |
NCT04172402 -
NGS as the First-line Treatment in Advanced Biliary Tract Cancer
|
Phase 2 | |
| Withdrawn |
NCT02597465 -
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
|
Phase 3 | |
| Active, not recruiting |
NCT04969887 -
Combination Immunotherapy in Rare Cancers Under InvesTigation
|
Phase 2 | |
| Recruiting |
NCT04211168 -
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
|
Phase 2 | |
| Recruiting |
NCT05812430 -
Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
|
Phase 2 |